Vaccine Innovators Convene to Discuss New Technologies
News Mar 18, 2013
Keynote Speaker Dr. Robin Robinson, Deputy Assistant Secretary and Director Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, will lead off the three-day conference with a presentation titled “Flexible Manufacturing & Synthetic Biology Converge Towards New Defense against Threats.”
Leading scientists, business leaders and regulatory agency representatives from around the world are gathered for the scientific conference to exchange information on bringing life-saving vaccines and antibodies to market more quickly through innovative manufacturing processes. At the conference, world-leading scientists will share how these advances significantly impact responsiveness to life-threatening infectious disease epidemics and bioterrorism threats.
The event is hosted by plant-based vaccine production pioneer, Fraunhofer USA Center for Molecular Biotechnology (CMB), located at the Delaware Technology Park in Newark, Delaware, and is conducted in cooperation with the International Association for Biological Standardization (IABS), headquartered in Geneva, Switzerland.
New Advances in Vaccine Production Proven Safe, Efficient and Effective
With the growing global demand for vaccines and other biologics, development of new, alternative production technologies is critical. The latest advancements in protein production include the use of stem cell, insect cell and plant systems.
“Through the conference,” Executive Director, Fraunhofer USA Center for Molecular Biotechnology and member of the conference organizing committee Dr. Yusibov said, “we hope to exchange information about the progress made by these new technologies in the past several years and spur collaboration for additional discoveries among representatives from academic research and the biotechnology and pharmaceutical industries.”
With a focus on getting to market, topics to be discussed during the three-day conference include progress through clinical trials, technology transfer, and regulatory considerations for new technologies.